COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
前收盤價
US$8.05
−US$0.60 · -6.94%
盤中時間採用ET。市場資料可能有所延遲。
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
日內區間
目前US$8.05
52週區間
目前US$8.05
盤中時間採用ET。市場資料可能有所延遲。
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
日內區間
目前US$8.05
52週區間
目前US$8.05
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1.18億 USD | 1.19億 USD | 8751.8萬 USD | 6505.3萬 USD | 4402.7萬 USD |
| 銷售、一般及管理費用 | 6060.1萬 USD | 5916.6萬 USD | 4940.1萬 USD | 4535萬 USD | 3919.4萬 USD |
| 營業費用 | 1.79億 USD | 1.78億 USD | 1.37億 USD | 1.1億 USD | 8322.1萬 USD |
| 利息收入 | 718.2萬 USD | 826.8萬 USD | 462.3萬 USD | — | — |
| 利息支出 | 451.7萬 USD | 447.9萬 USD | 220.4萬 USD | — | — |
| 折舊和攤銷 | 21.6萬 USD | 23.3萬 USD | 24.2萬 USD | 33萬 USD | 17.5萬 USD |
| 營業利益 | −1.79億 USD | −1.78億 USD | −1.37億 USD | −1.1億 USD | −8322.1萬 USD |
| 淨利 | −2.88億 USD | −1.55億 USD | −1.18億 USD | −9150.5萬 USD | −7174.2萬 USD |
公司資料更新於 2026年11月22日。
第三方分析師預期可能變動,並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
ARK Genomic Revolution ETFARKG4855.79萬2.79%22.11億 USD0.75%US$38.00-5.64%
iShares Biotechnology ETFIBB709.04萬0.07%105.27億 USD0.44%US$199.54-2.05%
AdvisorShares Psychedelics ETFPSIL397.99萬10.96%3631.88萬 USD1.28%US$16.68-4.63%
ALPS Medical Breakthroughs ETFSBIO136.48萬0.80%1.71億 USD0.50%US$50.95-3.01%
T. Rowe Price Small-Mid Cap ETFTMSL124.62萬0.04%31.37億 USD0.55%US$38.96-2.79%
State Street SPDR S&P International Small Cap ETFGWX87.46萬0.10%8.66億 USD0.40%US$39.93-3.11%
Simplify Propel Opportunities ETFSURI72.76萬1.12%6508.23萬 USD2.84%US$14.92-1.97%
ROBO Global Healthcare Technology and Innovation ETFHTEC63.99萬0.72%8859.16萬 USD0.80%US$41.07-2.14%
ARK Genomic Revolution ETFARKG
iShares Biotechnology ETFIBB
AdvisorShares Psychedelics ETFPSIL
ALPS Medical Breakthroughs ETFSBIO
T. Rowe Price Small-Mid Cap ETFTMSL
State Street SPDR S&P International Small Cap ETFGWX
Simplify Propel Opportunities ETFSURI
ROBO Global Healthcare Technology and Innovation ETFHTECAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。